Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001943462-26-000004
Filing Date
2026-02-17
Accepted
2026-02-17 09:55:31
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9742
2 TENX_ex1.pdf EX-1 47124
  Complete submission text file 0001943462-26-000004.txt   76813
Mailing Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517
Business Address 101 GLEN LENNOX DRIVE SUITE 300 CHAPEL HILL NC 27517 919-855-2100
TENAX THERAPEUTICS, INC. (Subject) CIK: 0000034956 (see all company filings)

EIN.: 262593535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-58467 | Film No.: 26637411
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 283 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830
Business Address 283 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830 203-632-6341
Dellora Investments LP (Filed by) CIK: 0001943462 (see all company filings)

EIN.: 850748545 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A